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AutoimmunityEfforts for the identiﬁcation of diagnostic autoantibodies for neuro-Behcet's disease (NBD) have failed. Screening
of NBD patients' serawith proteinmacroarray identiﬁedmitochondrial carrier homolog 1 (Mtch1), an apoptosis-
related protein, as a potential autoantigen. ELISA studies showed serum Mtch1 antibodies in 68 of 144 BD
patients with or without neurological involvement and in 4 of 168 controls corresponding to a sensitivity of
47.2% and speciﬁcity of 97.6%. Mtch1 antibody positive NBD patients had more attacks, increased disability and
lower serum nucleosome levels. Mtch1 antibody might be involved in pathogenic mechanisms of NBD rather
than being a coincidental byproduct of autoinﬂammation.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Behçet's disease (BD) is a chronic, recurrent and inﬂammatory dis-
order characterized with oral and genital aphthous ulcerations, uveitis,
skin lesions and skin pathergy reaction (Gül, 2005; Yurdakul and
Yazici, 2008). The presence of inﬂammatory lesions in involved tissues,
increased levels of cytokines and acute phase reactants and identiﬁca-
tion of autoantibodies [directed against heat shock proteins (HSP)-60,
-65 and -70, αB-crystallin, stress-induced-phosphoprotein 1, PTEN-
induced putative kinase 1 (PINK1), α-enolase, cyclic citrullinated pep-
tide, annexins and Saccharomyces cerevisiae antigens] in circulation
of BD patients have suggested an autoimmune as well as an auto-
inﬂammatory pathogenesis (Taşçi et al., 1998; Tanaka et al., 1999;
Celet et al., 2000; Dinc et al., 2003; Duygulu et al., 2005; Fresko et al.,, Istanbul University, Istanbul
l.: +90 212 4142000x32580;
ights reserved.2005; Gül, 2005; Koca et al., 2007; Birtas-Atesoglu et al., 2008; Lee
et al., 2009; Vural et al., 2009; Iaccarino et al., 2011; Vural et al., 2011).
Central nervous system (CNS) involvement, or neuro-Behçet's dis-
ease (NBD), develops in 5–10% of BD patients and generally afﬂicts
the brain parenchyma and less frequently the brain vessels and
meninges (Akman-Demir et al., 1999). The cerebral parenchymal
lesions are mainly composed of mononuclear and neutrophilic inﬁl-
trates (Hirohata, 2008). Nevertheless, NBD associated serum and
cerebrospinal ﬂuid (CSF) antibodies to αB-crystallin and HSP-60,
-65 and -70 have also been identiﬁed suggesting involvement of
antibody-mediated pathogenic mechanisms in NBD (Taşçi et al., 1998;
Tanaka et al., 1999; Celet et al., 2000; Birtas-Atesoglu et al., 2008). How-
ever, these antibodies have been detected in less than 30% of NBD
patients, and are thus, of limited use as biomarkers of the disease. In
an attempt to identify NBD-speciﬁc anti-neuronal antibodies, sera of
NBD patients and controls were screened using a protein macroarray,
and conﬁrmatory immunohistochemistry and immunoblotting studies
were performed. These studies identiﬁedmitochondrial carrier homolog
1 (Mtch1) autoantibody, which appears to be highly sensitive and spe-
ciﬁc for NBD and BD.
Fig. 1. Coomassie blue-stained 10% SDS-PAGE analysis of puriﬁcation of mitochondrial car-
rier homolog 1 (Mtch1) yielding a band at around 40 kDa, as predicted (leftmost column),
and representative immunoblots for Western blot analysis of recombinant Mtch1 protein
(remaining 5 columns). While both commercially available rabbit anti-human Mtch1 anti-
body (Mtch1-Ab) and neuro-Behçet's disease (NB) patients' sera thatwere found to be pos-
itive forMtch1 Ab by ELISA (NB p) yielded ~40 kDa bands at theMtch1 protein loaded gels,
NB sera that were seronegative for Mtch1 Ab by ELISA (NB n) did not show any bands.
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2.1. Patients and samples
Thirty-two consecutive NBD patients (13 women, 19 men; mean
age ± standard error, 36.4 ± 1.7) were included. The average NBD
duration (±standard error) of these patients was 9.9 ± 1.3 years.
Age- and gender-matched controls included 112 BD patients without
neurological involvement (41 women, 71 men; mean age, 37.3 ± 1.6;
disease duration 9.6 ± 2.3), 47 patients with relapsing remittingmulti-
ple sclerosis (25 women, 22 men; mean age, 34.3 ± 1.1; disease dura-
tion 9.6 ± 2.1), 21 neuromyelitis optica (NMO) patients (12 women,
9 men; mean age, 32.6 ± 1.5; disease duration 8.7 ± 1.3) and 100
healthy controls (47 women, 53 men; mean age, 35.7 ± 1.9). There
were no statistically signiﬁcant differences between NMO patients and
control groups by means of age, gender and disease duration (p N 0.05
by Fisher's exact test or Student's t-test). None of the patients had a
history of a concomitant neurological disease. NBD and BD patients
fulﬁlled the diagnostic criteria for BD (International Study Group for
Behçet's Disease, 1990), MS patients fulﬁlled McDonald's criteria for
deﬁniteMS (Polman et al., 2005) and NMO patients fulﬁlled the revised
Wingerchuk criteria (Wingerchuk et al., 2006). EDSS scores of NBD
patients were calculated during serum sampling. An informed consent
was obtained from all participants before blood samples were obtained.
Sera were kept frozen at−80 °C until assayed. Blood samples were col-
lected from all NBD and BD patients prior to the initiation of steroid
treatment, especially when the sample was obtained during an attack.
However, the interference of immunosuppressive therapy with anti-
body levels could not be completely avoided. While all NBD patients
were under long term azathioprine treatment when sera were collect-
ed, 58 BD patients were under immunosuppressive treatment and 54
BD patients were not receiving any immunosuppressants. The study
was approved by the Ethics Committee of Istanbul Faculty of Medicine
of Istanbul University.
2.2. Protein macroarray, sequencing of cDNA inserts and protein expression
To identify NBD related anti-neuronal antibodies, pooled sera of 10
randomly selected NBD patients were screened using a high-density
protein macroarray derived from human fetal brain cDNA expression
library, which contains approximately 24,000 clones (ImaGenes, Berlin,
Germany) (Preuss et al., 2009). Images were captured and analyzed for
signal intensity (VisualGrid, GPC Biotech, Martinsried, Germany). The
arrayswere scored as 0 (absent), 1 (weak), 2 (moderate) and 3 (strong)
conﬁrmed by matched duplicates. Selected expression clones were
obtained from ImaGenes. Plasmid DNA from clones was isolated for
DNA sequencing (Qiagen, Hilden, Germany) according to the
manufacturer's instructions. Cloned cDNAs in the puriﬁed plasmid
DNAwere sequenced by Iontek Laboratory (Istanbul, Turkey). Nucle-
otide and translated amino acid sequences were compared with
known sequences using BLAST algorithms (National Center for Bio-
technology Information, Bethesda, MD). Following the conﬁrmation of
the selected clone, His-tagged protein was recombinantly expressed
in Escherichia coli, puriﬁed by afﬁnity chromatography and the purity
of the proteinwas documented by SDS-PAGE analysis (Fig. 1), as report-
ed previously (Preuss et al., 2009).
2.3. Immunoblotting analyses
The puriﬁed protein was denatured (100 °C, 5 min), 1 μg puriﬁed
protein was loaded in each lane, electrophoresed (10% acrylamide
gel) and transferred to 0.45-μm polyvinylidene ﬂuoride membranes
(100 V, 80 min). Membranes were blocked (5% milk in TBST; 90 min)
and incubated with individual human sera (diluted 1:200) or commer-
cially available rabbit anti-human antibody (1:200 dilution) (Santa Cruz
Biotechnology, Santa Cruz, CA) followed by HRP-conjugated goat anti-human IgGor goat anti-rabbit IgG (Jackson ImmunoResearch Laboratory)
at 1:1000 dilutions. Immunoreactivity was visualized on chemilumines-
cent ﬁlm using ECLWestern blotting substrate (Pierce, Thermo Scientiﬁc,
USA) according to the manufacturer's instructions (Fig. 1).
2.4. ELISA
Detection of antibodies to the puriﬁed recombinant human protein
was performed with ELISA. The puriﬁed protein (50 μl at 10 μg/ml)
was added to the wells of a 96-well high-binding-capacity plate and
incubated overnight at 4 °C. Wells coated with the E. coli lysate or
only with bovine serum albumin were used as controls. The plates
were washed with TBST and blocked for 2 h with 5% skim milk in TBS.
A 60 μl aliquot of each serum sample (diluted 1:100) in TBST was
added to protein coated wells and incubated for 2 h at room tempera-
ture. The plates were washed six times with TBST followed by the addi-
tion of 60 μl of alkaline phosphatase-conjugated goat anti-human IgG
(Southern Biotech, Birmingham, AL, USA) diluted 1:2000 in TBST and
then incubated at room temperature for 1 h. After washing, 60 μl of
2-(2-benzothiazoyl)-6-hyroxybenzothiazole phosphate was added for
45 min at room temperature followed by addition of the stopping solu-
tion (3 N NaOH). Fluorescent signals were measured at 450/50 excita-
tion and 580/50 emission with a microplate reader. For each sample,
the value obtained from the protein-coated well was substracted from
the non-coated well. The obtained results were expressed as signal
ratios (sample signal/mean signal of healthy controls). Positivity was
deﬁned as 2 standard deviations above the mean of healthy controls.
2.5. Immunohistochemistry and colocalization studies on rat brain sections
Whole rat brain was treated ﬁrst with 4% paraformaldehyde over-
night at 4 °C, immersed in 40% sucrose overnight at 4 °C and subse-
quently snap frozen in liquid nitrogen. Seven μm-thick frozen sections
were serially incubated with 0.3% H2O2 for 20 min, 10% goat serum
for 1 h at room temperature and serum samples (1:200) overnight at
4 °C. They were then incubated in biotinylated goat anti-human IgG
141B. Vural et al. / Journal of Neuroimmunology 263 (2013) 139–144(1:2000, Vector Laboratories, Burlingame, CA), and the immunoreac-
tivity developed by serial incubation with avidin–biotin peroxidase
(Vector Laboratories) for 1 h and diaminobenzidine (Irani et al., 2010).
For immunoﬂuorescence experiments, frozen and paraformaldehyde-
ﬁxed rat brain sections were incubated with 10% goat serum for 1 h at
room temperature followed by patients' sera (1:200) and commercial
rabbit anti-rat Mtch1 antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) at 1:200 dilution overnight at 4 °C. Next day, sections
were incubated with Alexa Fluor 488-conjugated anti-human IgG
and Alexa Fluor 568-conjugated anti-rabbit IgG (1:2000 dilution)
(Invitrogen, Paisley, UK) for 2 h at room temperature. Sections were
evaluated and photographed under a Zeiss ﬂuorescence microscope
with a digital camera using the Zeiss Axiovision software. Moderate
to strong Alexa Fluor 488-conjugated anti-human IgG-induced green
color that overlapped with Alexa Fluor 568-conjugated anti-rabbit
IgG-induced red color was considered as colocalization.
2.6. Quantitation of circulating nucleosomes
Intensity of apoptosis was estimated in NBD patients and healthy
controls by measuring serum levels of circulating nucleosomes with a
quantitative sandwich-enzyme-immunoassay, using mouse monoclonal
antibodies directed against DNA and histones, respectively. This method
allowed speciﬁc detection and quantitation of histone-associated DNA
fragments in mono- and oligonucleosomes (a marker for apoptotic
cells) that are released into serum. Serum levels of nucleosomes were
measured as per manufacturer's protocol (Roche Applied Science,
Indianapolis, IN, US).
2.7. Statistics
Demographic and clinical features of NBD patients were compared
using Fisher's exact test, Student's t-test orMann–WhitneyU test, as ap-
propriate. Signal ratios obtained in ELISA experiments were compared
among groups by ANOVA and Tukey's post-hoc test. Serum nucleosome
levels were compared with Student's t-test. Correlation statistics wereFig. 2. ELISA detection of IgG antibodies directed against mitochondrial carrier homolog 1 (Mtch1
logical involvement (BD), multiple sclerosis patients (MS), neuromyelitis optica patients (NMO) a
of the healthy control samples (cut-off values for positivity). Horizontal lines indicate the mean vperformed with parametric Pearson's or non-parametric Spearman's
correlation tests, as required. A p value smaller than 0.05 was consid-
ered as statistically signiﬁcant.
3. Results
3.1. Identiﬁcation and veriﬁcation of Mtch1 antibody
To identify target antigens of NBD-associated neuronal autoanti-
bodies, a protein macroarray derived from a human fetal brain cDNA
expression library was used to screen sera from NBD patients. A single
clone with the highest signal intensity and number of duplicates
(n = 3) was selected for further investigation. DNA sequencing and
BLAST analysis of the clone yielded a single oligonucleotide that
corresponded to 92% of the sequence of Mtch1 (GenBank accession
number, NM_014341). A Mtch1 his-tagged fusion protein was re-
combinantly produced in E. coli and puriﬁed by afﬁnity chromatography.
SDS-PAGE analysis showed a single band at around 40 kDa, consistent
with the predicted molecular weight, conﬁrming the purity of the
obtained protein (Fig. 1).
ELISA studies performed with the recombinant protein revealed
high-titer autoantibodies in 18 of 32 (56.3%) NBD, 50 of 112 (44.6%)
BD, 3 of 47 (6.4%) multiple sclerosis, 1 of 21 (4.8%) neuromyelitis optica
patients and none of the healthy controls (Fig. 2). Overall, 68 of 144
(47.2%) BD patients with or without neurological involvement and 4
of 168 (2.4%) non-BD controls displayedMtch1 antibody corresponding
to a sensitivity of 47.2% at 97.6% speciﬁcity. NBD and BD patients had
signiﬁcantly higher signal ratio values as compared to control groups
(p b 0.0001 by ANOVA and p b 0.05–0.001 by Tukey's post-hoc test,
Fig. 2). None of the sera reacted with the lysate of the E. coli strain
used to express the proteins or irrelevant proteins (myc-associated
zinc ﬁnger protein and zinc ﬁnger protein 553) expressed by the same
E. coli strain (data not shown), supporting the speciﬁcity of the autoan-
tibody measurements. There were no signiﬁcant differences between
average signal ratios of BD patients with (2.3 ± 1.9) or without
(2.6 ± 1.7) immunosuppressive treatment (p = 0.148 by Student's) in sera of neuro-Behçet's disease (NBD) patients, Behçet's disease patients with no neuro-
nd healthy controls. The dashed lines represent 2 standard deviations (2SD) above themean
alue of each group. *, p b 0.05; **, p b 0.01; ***, p b 0.001 by Tukey's post-hoc test.
142 B. Vural et al. / Journal of Neuroimmunology 263 (2013) 139–144t-test). Mtch1 antibody seropositivity rates were also comparable
among both groups (23/58 patients with immunosuppression vs
27/54 patients without immunosuppression, p = 0.431 by Fisher's
exact test).
The antibody binding to Mtch1 was conﬁrmed by Western blotting
using puriﬁedMtch1 protein. Both the commercially available antibody
to Mtch1 and the seropositive NBD sera reacted with a band at the pre-
dicted 40 kDa, whereas seronegative sera did not show any immunore-
activity (Fig. 1). In immunohistochemistry studies, serum IgGs of Mtch1
antibody positive NBD patients showed strong cytoplasmic reactivity
with neurons located throughout thewhole brain section, including cer-
ebellar Purkinje cells and cortical neurons (Fig. 3A,B), whereas those of
Mtch1 antibody negative NBD patients did not show any appreciable
immunoreactivity. Mtch1 is located at the mitochondrial membrane
and is thus a cytoplasmic protein (Xu et al., 2002; Lamarca et al.,
2007). Therefore, the cytoplasmic staining pattern obtained by NBD
sera was considered to be due to immunoreactivity with neuronal
Mtch1 protein. Immunoﬂuorescence studies performed with sera of
NBD patients and a commercially available Mtch1 antibody revealed a
signiﬁcant co-localization of reactivities with seropositive (Fig. 3C–E)
but not seronegative (Fig. 3F–H) serum samples, further conﬁrming
the presence of Mtch1 antibodies.Fig. 3. Immunolabeling of frozen rat brain sections with mitochondrial carrier homolog 1 antib
immunoperoxidase (A,B) and immunoﬂuorescence (C–H) studies show intense reactivity wit
neurons (B). Double immunolabeling of cerebellar sections with Mtch1-Ab (C, green) and a co
localization of reactivities (D, yellow). By contrast, a Mtch1-Ab seronegative NBD patient's seru
niﬁcation for panels A andB is×100 and for panels C–H is×40. Staining for panels A and Bwas p3.2. Comparison of clinical features among Mtch1 antibody positive and
negative NBD patients
NBD patients with and without Mtch1 antibodies did not signiﬁ-
cantly differ in terms of gender, age, clinical course, disease duration,
neurological disability and pathergy test positivity. Although a higher
antibody positivity rate was observed in samples obtained during a
neurological attack, this difference did not attain statistical signiﬁcance
(p = 0.165 by Fisher's exact test). By contrast, Mtch1 antibody positive
patients had signiﬁcantly higher number of NBD attacks prior to
blood sampling than Mtch1 antibody negative patients (p = 0.024
by Student's t-test). Also, Mtch1 antibody positive patients showed
trends towards exhibiting higher Expanded Disability Status Scale
(EDSS) scores (p = 0.094 by Mann–Whitney U) and parenchymal
rather than vascular NBD ﬁndings (p = 0.142 by Fisher's exact test)
(Table 1).
3.3. Differential apoptotic cell death in Mtch1 antibody positive and
negative patients
Mtch1 has been implicated to take part in apoptotic cell deathmech-
anisms (Xu et al., 2002; Lamarca et al., 2007). To investigate whetherody (Mtch1-Ab) positive and negative sera of neuro-Behçet's disease (NBD) patients. Both
h the cytoplasm of neurons throughout the brain including Purkinje cells (A) and cortical
mmercially available antibody to Mtch1 (E, red) yield cytoplasmic staining; note the co-
m IgGs fail to react with the same location as commercial Mtch1-Ab (F–H). Original mag-
erformedwith the avidin–biotin–peroxidase techniquewith hematoxylin counterstaining.
Table 1
Comparison of clinical and demographic features of neuro-Behçet's disease (NBD) patients
with and without mitochondrial carrier homolog 1 antibodies (Mtch1-Ab).
Mtch1-Ab
negative
(n = 14)
Mtch1-Ab
positive
(n = 18)
p value
Gender (women/men) 6/8 7/11 1.000a
Age (mean ± SE) 34.8 ± 2.2 37.5 ± 2.6 0.216b
Patients with serum samples obtained
during an attack
4 10 0.165a
Patients with parenchymal/vascular NBD 7/7 14/4 0.142a
Duration of NBD during serum sampling
(years; mean ± SE)
10.6 ± 1.9 9.5 ± 1.7 0.342b
Number of attacks before serum sampling
(mean ± SE)
1.3 ± 0.1 1.8 ± 0.2 0.024b
Patients with positive pathergy test 8 9 0.734a
EDSS scores (mean ± SE) 1.5 ± 0.4 2.2 ± 0.4 0.094c
Patients with relapsing remitting/progressive
clinical course
12/2 17/1 0.568a
SE; standard error, CSF; cerebrospinal ﬂuid, EDSS; expanded disability status scale.
a Fisher's exact test.
b Student's t-test.
c Mann–Whitney U.
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sity of apoptosis was estimated in sera of 32 NBD patients and an equal
number of healthy controls (randomly selected from healthy control
samples used in ELISA studies) using a cell death detection kit based
on quantitation of circulating nucleosomes. NBD patients had signiﬁ-
cantly higher serum nucleosome levels than healthy controls (p =
0.0001 by Student's t-test, Fig. 4A). Notably, Mtch1 antibody positive
NBD patients had signiﬁcantly lower nucleosome levels than Mtch1
antibody negative NBD patients (p = 0.034 by Student's t-test, Fig. 4B).
In line with these results, Mtch1 antibody signal ratio values of NBD
patients were negatively correlated with their circulating nucleosome
levels (R = −0.474, p = 0.047 by Pearson's test).
4. Discussion
A number of autoantibodies have been described in serum and/or
CSF samples of NBD patients. Most of these are directed against stress-
related proteins, such as HSP-60, HSP-65, HSP-70, αB-crystallin and
stress-induced-phosphoprotein 1. Antibodies to PINK1, α-enolase,
cyclic citrullinated peptide and S. cerevisiae antigens have also been
identiﬁed. However, all of these antibodies are found only in a small
fraction (5–35%) of NBD patients and they can also be frequently detect-
ed in patients with other neuroinﬂammatory diseases lowering their
values as a diagnostic biomarker (Taşçi et al., 1998; Tanaka et al.,
1999; Celet et al., 2000; Fresko et al., 2005; Koca et al., 2007; Birtas-
Atesoglu et al., 2008; Lee et al., 2009; Vural et al., 2009; Vural et al.,
2011). Annexin-V antibodies are highly prevalent in NBD and BD pa-
tient cohorts (Gheita et al., 2012), but can be detected in a plethora ofFig. 4. Intensity of apoptosis in neuro-Behcet's disease (NBD) patients vs healthy controls (A) a
(B) estimated by serum levels (OD) of circulating nucleosomes measured using a cell-death derheumatological disorders (Iaccarino et al., 2011) and the prevalence
in other neuroinﬂammatory disorders is currently unknown. The novel
Mtch1 antibody described in this study does not only add a newmember
to the list of NBD-associated antibodies but also appears to be a potential
diagnostic biomarker with its high frequency in NBD patients and low
prevalence in other neuroinﬂammatory diseases that are in the differen-
tial diagnosis list of NBD such as multiple sclerosis.
Presently, the only reliable diagnostic test for BD and NBD is the
pathergy test, which also constitutes a part of the BD diagnostic criteria.
However, problems with standardizing the induction method, needle
size and type as well as the method of assessment of the response
have limited the usefulness of this test in the clinical setting. Also, the
prevalence of a positive pathergy test in BD varies among countries
and test centers. Sensitivity of the pathergy test ranges between 30%
and 45% at speciﬁcities of 87% to 100% (Dilşen et al., 1993; Chang and
Cheon, 2002; Ozdemir et al., 2008; Davatchi et al., 2011). The sensitivity
and speciﬁcity values of Mtch1 antibodies for NBD and BD patients
in our study were easily comparable with those of pathergy test. As a
matter of fact, the frequency of Mtch1 antibody seropositivity in our
NBD cohort (56.3%) was higher than that of pathergy test positivity
(53.1%). Therefore, ELISA-based Mtch1 antibody measurement might
potentially be utilized as a reliable, easy-to-use, noninvasive and stan-
dard diagnostic method.
NBD almost always develops several years after the onset of BD
(Akman-Demir et al., 1999) and thus NBD patients are generally
under immunosuppressive treatment. Although we managed to avoid
the effects of steroid treatment on Mtch1 seropositivity, since all of
our NBD patients were under long-term follow-up as BD patients, we
could not compare Mtch1 antibody levels in naïve and immuno-
suppressed NBD patients. Nevertheless, this comparison was made
among BD patients. Although non-immunosuppressed BD patients
showed trends towards exhibiting slightly higherMtch1 antibody levels
than immunosuppressed BD patients, this difference did not reach
statistical signiﬁcance, suggesting that measurement of Mtch1 antibody
is not signiﬁcantly affected from immunosuppression and lower Mtch1
antibody seropositivity rates in the BD group is not related with the dif-
ferences in treatment status. However, for a better assessment of the
speciﬁcity of Mtch1 antibody, patients with non-inﬂammatory CNS dis-
orders as well as other vasculitic–rheumatological disorders need to be
studied.
Based on the molecular mimicry between stress induced proteins
and certain proteins expressed by microorganisms, it has recently
been proposed that HSP antibodies develop as a result of the immune
reaction against invading pathogens and coincidentally crossreact with
human tissue thus causing BD symptoms (Ghasemi et al., 2012). How-
ever, our extensive search in National Center for Biotechnology Informa-
tion GenBank using BLAST and CLCMainWorkbench software has failed
to ﬁnd any considerable identity between Mtch1 and proteins of a wide
range of microorganisms (data not shown). Moreover, Mtch1 antibody's
association with NBD disease severity and apoptotic cell death ratesnd NBD patients with vs without mitochondrial carrier homolog 1 antibodies (Mtch1-Ab)
tection ELISA kit. *; p b 0.05, ***; p b 0.001 by Student's t-test.
144 B. Vural et al. / Journal of Neuroimmunology 263 (2013) 139–144suggests that Mtch1 antibody is not a bystander side effect of auto-
inﬂammation andmight have certain pathogenic functions in NBD path-
ogenesis. It is well known that, in BD, an increased occurrence of
apoptotic cell death is observed in parenchymal lesions of CNS as well
as other involved tissues (Hirohata, 2008). Notably, both Mtch1 and
recently identiﬁed BD autoantigen annexin-V are associated with apo-
ptosis and levels of antibodies to both antigens are correlated with dis-
ease severity (Xu et al., 2002; Lamarca et al., 2007; Iaccarino et al.,
2011; Gheita et al., 2012). Mtch1 is a proapoptotic protein, Mtch1 anti-
bodies tend to occur in patients with a more severe disease course and
patients with Mtch1 antibodies exhibit reduced intensity of apoptotic
cell death, altogether suggesting that Mtch1 antibodies might plausibly
be developing as a protective mechanism to reduce and neutralize the
tissue damage afﬂicted by BD associated autoinﬂammation. Antibodies
to progranulin, a protein associated with frontotemporal dementia,
have recently been discovered in vasculitis patients (Thurner et al.,
2012). Notably, Mtch1 is closely associated with presenilin, the dysfunc-
tion of which might cause Alzheimer's disease (Xu et al., 2002; Lamarca
et al., 2007). Whether these recent ﬁndings point to a possible link
betweenneurodegeneration andneuroinﬂammation requires to be scru-
tinized in future studies.
In conclusion, Mtch1 antibody seropositivity appears to have a con-
siderable sensitivity and speciﬁcity for NBD and BD. The association be-
tween Mtch1 antibody levels and clinical and apoptotic parameters of
NBD suggests that Mtch1 antibody might have a pathogenic action.
Therefore, further characterization of the functional role of Mtch1 anti-
body is warranted.References
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